

# Symptoms of children and adolescents infected with SARS-CoV-2 variants alpha, delta or omicron

1

2 **Hansjörg Schulze<sup>1</sup>, Wibke Bayer\***

3 <sup>1</sup> Institute for Virology, University Hospital Essen, University Duisburg-Essen, Essen, Germany

4 **\* Correspondence:**

5 Wibke Bayer

6 [wibke.bayer@uk-essen.de](mailto:wibke.bayer@uk-essen.de)

7 **Keywords: SARS-CoV-2, symptoms, children, adolescents, mild disease**

8

9

## 10 **Abstract**

11 Symptoms experienced by children and adolescents with SARS-CoV-2 infections in the alpha, delta  
12 and omicron variant dominated phases were investigated using an online survey, and the frequencies  
13 of reported symptoms and changes over time were analyzed. The most prevalent symptoms were  
14 fever above 38 °C, tiredness, headache, runny or blocked nose, sneezing and dry cough. Lethargy and  
15 nausea were reported significantly more frequently in the omicron variant dominated phase than in  
16 the earlier phases of the pandemic. Compared to symptoms reported by adults, fever and  
17 gastrointestinal symptoms were reported more frequently for children, especially in the omicron  
18 variant dominated phase, whereas the frequency of loss of smell and loss of taste was significantly  
19 lower in children than in adults.

20

## 21 **Introduction**

22 The SARS-CoV-2 pandemic started in late 2019 in Wuhan, China, where the first cases and human-  
23 to-human transmission were reported [1], and the virus spread quickly all over the world. By August  
24 2023, more than 769 million people have been infected according to data from the World Health  
25 Organization [2], which is very likely an underestimate since testing for SARS-CoV-2 has been

26 reduced significantly since spring 2023 as SARS-CoV-2 has no longer been considered a public  
27 health emergency [3].

28 SARS-CoV-2 can induce severe disease in adults as well as in children, but mild disease is most  
29 common in both children and adults. The rate of asymptomatic infections is generally hard to  
30 determine and reported numbers vary widely; different meta-analyses calculated asymptomatic  
31 infection rates in children in the earlier phases of the pandemic of 19.3% [4], 13.1% [5] or 46.7% [6].  
32 In the symptomatic infections, cough, nausea, vomiting and diarrhea have been reported as the most  
33 frequent symptoms of children during the early, SARS-CoV-2 D614G dominated phase of the  
34 pandemic [5]. For later, variant-dominated phases, increases in the frequency of fever, cough and  
35 upper respiratory tract symptoms have been described [7].

36 We have previously reported on a detailed study of self-reported symptoms by SARS-CoV-2 infected  
37 adults during four different phases of the pandemic, where we determined the frequency of more than  
38 40 different symptoms and analyzed changes in the variant-dominated phases [8]. Our new data now  
39 provide detailed insight into symptoms experienced by SARS-CoV-2 infected children in phases of  
40 the pandemic that were dominated by different SARS-CoV-2 variants, and we present a side-by-side  
41 comparison with symptom frequencies reported by adults.

42

## 43 **Methods**

### 44 **Ethics Approval**

45 The study was approved by the local Ethics Committee of the Medical Faculty of the University  
46 Duisburg-Essen (approval number 20-9233-BO). The study was carried out in accordance with the  
47 ethical guidelines and regulations. The study participants and a parent or another legal representative  
48 gave their informed consent to their voluntary participation in the study and to the subsequent use of  
49 the data for publication.

### 50 **Data collection**

51 Data were obtained using an online questionnaire based on the LimeSurvey software which was  
52 hosted on the servers of the University Duisburg-Essen. Participants for the study were recruited via  
53 the public health offices of the administrative district of Soest (North Rhine-Westphalia, Germany)

54 and of the administrative district Hochsauerlandkreis (North Rhine-Westphalia, Germany) when they  
55 received their confirmation of a positive SARS-CoV-2 PCR test result. The data presented in this  
56 manuscript were collected between January 23<sup>rd</sup> 2021 and March 22<sup>nd</sup> 2022. During this time, official  
57 SARS-CoV-2 antigen testing was accessible in Germany when a SARS-CoV-2 infection was  
58 suspected with or without respiratory symptoms or prior contact. Semi-weekly self-testing or pool-  
59 testing was introduced from April 2021 for children visiting a kindergarten or school. An individual  
60 PCR test was mandatory after a positive official or at-home antigen test or pool PCR test. Official  
61 PCR test results and resulting quarantines were managed by the public health offices.

## 62 **Data analysis**

63 Data were analyzed using R (version 3.6.3) and RStudio software and fmsb, plyr, splyr, tidyverse,  
64 reshape2, stats, ggplot2 and viridis packages. Only data from individuals who had completed the  
65 survey were included in the analysis.

66 For graphical representation, a heatmap of the data was created with ggplot2 after sorting the  
67 responses by the date of survey completion and by the age of the respondents. The category “fever >  
68 38.0 °C” was added after calculation from the survey responses using the tidyverse package.

69 The test for statistically significant differences in symptom frequencies between SARS-CoV-2  
70 infected children in the alpha, delta and omicron variant dominated phases and in symptom  
71 frequencies between children from the current survey and adults from our previous symptom study  
72 [8] was performed using Fisher’s exact test using the function fisher.test of the R stats package. The  
73 test for statistically significant differences in the age distribution of the respondents from the alpha,  
74 delta and omicron variant dominated phases was performed by One Way analysis of variance (One  
75 Way ANOVA) using the function aov() of the R stats package.

76

## 77 **Results**

78 An online based survey was performed to gather information on the prevalence of different  
79 symptoms in children and adolescents after infection with SARS-CoV-2. Participants were recruited  
80 by their local health office. In total, 101 responses were obtained from or for children and adolescents  
81 aged between 0 years and 18 years (Table 1). The study started in January 2021 during the SARS-  
82 CoV-2 alpha variant dominated phase (in Germany: February 2021 – June 2021), and data were

83 collected over a period of more than a year, thus also covering the delta variant (July 2021 – January  
84 2022) and omicron variant dominated phases (from January 2022; [9]). The major characteristics of  
85 the participants from the three phases are comparable, with a majority of respondents between 7 and  
86 12 years old. The subjective assessment of the severity of the infection, ranging from asymptomatic  
87 over mild (e.g.: “symptoms without feeling ill”) and moderately ill (e.g.: “feeling ill and lying on  
88 sofa”) to very ill (e.g.: “feeling ill and having to stay in bed”) resulted in a majority (overall 50.5%,  
89 alpha: 58.3%, delta: 43.2%, omicron: 55.6%) of respondents answering with “moderately ill”. Only a  
90 minority of 5.9% overall (alpha: 8.3%, delta 11.4%, omicron 0%) reported an asymptomatic  
91 infection. None of the respondents reported a hospitalization or the necessity of intensive care  
92 treatment due to the SARS-CoV-2 infection (0%).

93 The symptoms reported by the survey respondents are shown in Figure 1A as a heatmap and as  
94 bargraphs in Figure 2. The most frequently reported symptoms included general symptoms such as  
95 fever, tiredness and headaches, and more specific respiratory symptoms such as a runny or blocked  
96 nose and dry cough. The comparison of the symptoms reported during the three different phases of  
97 the pandemic (Figure 2B), i.e. the alpha, delta, and omicron variant dominated phases, revealed only  
98 minor differences in symptom frequencies with the exception of blocked nose, which dropped from  
99 83.3% in the alpha variant dominated phase to 47.7% and 42.2.% during the delta and omicron  
100 variant dominated phases, respectively, and changes in the frequency of lethargy (alpha: 25%, delta:  
101 22.7%, omicron: 53.3%), loss of smell (alpha: 8.3%, delta: 18.2%, omicron: 4.4%) and nausea  
102 (alpha: 16.7%, delta: 9.1%, omicron: 33.3%). Importantly, differences observed in the three phases  
103 do not correlate to a difference in the age distribution of the respondents (Figure 1B, no significant  
104 differences, One Way ANOVA).

105 We have reported before on the results of a similar symptom survey where we gathered information  
106 about symptoms experienced by adults infected with SARS-CoV-2 [8]. Performing a side-by-side  
107 comparison, we found that symptom frequencies during all three variant dominated phases differed  
108 between adults and children, with most general symptoms such as lethargy (alpha: adults 60.5%,  
109 children 25%; delta: adults 50.2%, children 22.7%; (omicron: adults 46.5%, children 53.3%)),  
110 headache (alpha: adults 68.3%, children 58.3%; delta: adults 67.4%, children 47.7%; omicron: adults  
111 65.7%, children 60%), muscle pains (alpha: adults 31%, children 8.3%; delta: adults 28.4%, children  
112 11.4%; omicron: adults 30.4%, children 20%) and sweating (alpha: adults 21.9%, children 8.3%;  
113 delta: adults 28.4%, children 11.4%; omicron: adults 21%, children 6.7%) reported at significantly

114 lower frequency for SARS-CoV-2 infected children compared to SARS-CoV-2 infected adults  
115 (Figure 3). While the frequencies of the hallmark symptoms of SARS-CoV-2 infection, loss of smell  
116 and taste, were also significantly lower in children in all three variant dominated phases (loss of  
117 smell/taste, alpha: adults 48.2%/42%, children 8.3%/8.3%; delta: adults 60.6%/54.6%, children  
118 18.2%/18.2%; omicron: adults 25%/23.8%, children 4.4%/8.9%), other symptom frequencies were  
119 elevated in children compared to adults, notably the frequency of fever higher than 38 °C (alpha:  
120 adults 19.4%, children 41.7%; delta: adults 17.9%, children 47.7%; omicron: adults 16.6%, children  
121 44.4%) and gastrointestinal symptoms such as nausea (alpha: adults 19.4%, children 16.7%; delta:  
122 adults 12.9%, children 9.1%;) omicron: adults 11.7%, children 33.3%), vomiting (alpha: adults 2.7%,  
123 children 16.7%; delta: adults 1.8%, children 9.1%; omicron: adults 1.2%, children 26.7%), abdominal  
124 pain (alpha: adults 10.3%, children 25%; delta: adults 8.5%, children 15.9%; omicron: adults 8.9%,  
125 children 28.9%) and abdominal cramps (alpha: adults 6.5%, children 0%; delta: adults 5%, children  
126 4.5%;) omicron: adults 3.5%, children 11.1%).

127

## 128 **Discussion**

129 In this report, we provide a detailed analysis of the symptoms experienced by SARS-CoV-2 infected  
130 children, and show that the symptoms reported most often and at rates of more than 40% were fever  
131 above 38 °C, tiredness, headache, runny nose, blocked nose, sneezing and dry cough. It is interesting  
132 to note that in comparison to symptom frequencies reported by adults, we observed many minor  
133 differences, and a significantly higher frequency of fever and a strikingly lower frequency of loss of  
134 smell and taste was observed in children compared to adults.

135 It has been reported before that a very high percentage of SARS-CoV-2 infected children  
136 experienced fever, and rates in other reports are often even higher than the frequency reported by us  
137 [4; 5; 7]. We found that the frequency of fever above 38 °C was significantly higher in children  
138 compared to adults, which may be explained by the finding that the expression levels of type I  
139 interferons are higher in children than in adults [10; 11; 12; 13; 14].

140 The loss of smell and/or loss of taste has been considered a hallmark symptom of SARS-CoV-2  
141 infection since the beginning of the pandemic [15], and was shown by us [8] and others to have  
142 decreased in frequency in adults infected with SARS-CoV-2 since the spread of the SARS-CoV-2  
143 omicron variant [16] from a frequency around 60% to below 20%. The frequency in children

144 however was much lower in all three phases of the pandemic that we analyzed here, which is in  
145 agreement with findings by others; it was shown in a meta-analysis that the frequencies in individual  
146 studies varied markedly and that children of more than ten years of age were more likely to  
147 experience loss of smell or taste [17].

148 There are some limitations to our study, most importantly that the total number of respondents was  
149 low, and children below the age of 6 and between 13 and 18 years old are less represented than the  
150 age group of 7 to 12 years old. We were therefore not able to correlate symptom frequencies with age  
151 groups, and would also like to point out the relatively low number of respondents with regard to the  
152 comparison of symptom frequencies for the three different SARS-CoV-2 variants. Furthermore, the  
153 symptoms of SARS-CoV-2 infected children were either self-reported or reported by a parent and  
154 can be subjective, and the presence of some symptoms such as headache, joint pain or muscle pain  
155 can be difficult or impossible to assess or to distinguish in very young children. As is always the case  
156 with self-report questionnaires, there is a certain response bias in that it is more likely that infected  
157 individuals with symptoms, or in this case the parents of the young individuals, take part in the study  
158 than asymptomatic individuals. Even though a few individuals reported no symptoms, this rate  
159 should not be construed as the rate of asymptomatic infection. In many cases, the questionnaires were  
160 completed within a week after the positive PCR test, but in general the study has to be considered  
161 partly retrospective, which may have resulted in a less clear picture than a daily questionnaire. With  
162 regard to the attribution of the infections to a certain SARS-CoV-2 dominated phase, it has to be  
163 pointed out that infection with a certain variant was not confirmed and that the attribution was  
164 performed solely on the date of questionnaire completion. While the alpha, delta and omicron  
165 variants quickly replaced the respective preceding variants [9], there were short times of overlap  
166 when both variants were present, which slightly weakens the allocation of responses to the variants.  
167 Finally, we did not obtain information in this study about the duration of symptoms, and cannot  
168 assess how long individual symptoms persisted.

169 Overall, our study provides additional insight into the symptoms experienced by SARS-CoV-2  
170 infected children and adolescents and contributes to understanding this infection in the young.

171

## 172 **References**

173 [1] P.f.M.E. Disease, Undiagnosed Pneumonia - China (Hubei): Request for Information, 2019.

- 174 [2] G. World Health Organization, WHO COVID-19 Dashboard., Available online:  
175 <https://covid19.who.int/>, accessed: 2023-08-11.
- 176 [3] G. World Health Organization, World Health Organization Situations: Coronavirus disease  
177 (COVID-19) pandemic, Available online:  
178 <https://www.who.int/europe/emergencies/situations/covid-19>, accessed: 2023-08-11.
- 179 [4] A. Hoang, K. Chorath, A. Moreira, M. Evans, F. Burmeister-Morton, F. Burmeister, R. Naqvi, M.  
180 Petershack, and A. Moreira, COVID-19 in 7780 pediatric patients: A systematic review.  
181 *eClinicalMedicine* 24 (2020).
- 182 [5] O. Irfan, F. Muttalib, K. Tang, L. Jiang, Z.S. Lassi, and Z. Bhutta, Clinical characteristics,  
183 treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysis.  
184 *Archives of Disease in Childhood* 106 (2021) 440-448.
- 185 [6] P. Sah, M.C. Fitzpatrick, C.F. Zimmer, E. Abdollahi, L. Juden-Kelly, S.M. Moghadas, B.H.  
186 Singer, and A.P. Galvani, Asymptomatic SARS-CoV-2 infection: A systematic review and  
187 meta-analysis. *Proceedings of the National Academy of Sciences* 118 (2021).
- 188 [7] M.W. Sumner, J. Xie, R. Zemek, K. Winston, G. Freire, B. Burstein, A. Kam, J. Emsley, J.  
189 Gravel, R. Porter, V. Sabhaney, A. Mater, M.I. Salvadori, S. Berthelot, D. Beer, N. Poonai, A.  
190 Moffatt, B. Wright, S.B. Freedman, S. Ali, M. Newton, W. Alqurashi, M. Lorenzo, T.  
191 Crawford, and B. Emerton, Comparison of Symptoms Associated With SARS-CoV-2  
192 Variants Among Children in Canada. *JAMA Network Open* 6 (2023).
- 193 [8] H. Schulze, and W. Bayer, Changes in Symptoms Experienced by SARS-CoV-2-Infected  
194 Individuals – From the First Wave to the Omicron Variant. *Frontiers in Virology* 2 (2022).
- 195 [9] E.B. Hodcroft, CoVariants: SARS-CoV-2 Mutations and Variants of Interest. (2021).
- 196 [10] C.A. Pierce, S. Sy, B. Galen, D.Y. Goldstein, E. Orner, M.J. Keller, K.C. Herold, and B.C.  
197 Herold, Natural mucosal barriers and COVID-19 in children. *JCI Insight* 6 (2021).
- 198 [11] J. Loske, J. Röhmel, S. Lukassen, S. Stricker, V.G. Magalhães, J. Liebig, R.L. Chua, L.  
199 Thürmann, M. Messingschlager, A. Seegebarth, B. Timmermann, S. Klages, M. Ralser, B.  
200 Sawitzki, L.E. Sander, V.M. Corman, C. Conrad, S. Laudi, M. Binder, S. Trump, R. Eils,  
201 M.A. Mall, and I. Lehmann, Pre-activated antiviral innate immunity in the upper airways  
202 controls early SARS-CoV-2 infection in children. *Nature Biotechnology* 40 (2021) 319-324.
- 203 [12] M. Yoshida, K.B. Worlock, N. Huang, R.G.H. Lindeboom, C.R. Butler, N. Kumasaka, C.  
204 Dominguez Conde, L. Mamanova, L. Bolt, L. Richardson, K. Polanski, E. Madissoon, J.L.  
205 Barnes, J. Allen-Hyttinen, E. Kilich, B.C. Jones, A. de Wilton, A. Wilbrey-Clark, W.  
206 Sungnak, J.P. Pett, J. Weller, E. Prigmore, H. Yung, P. Mehta, A. Saleh, A. Saigal, V. Chu,  
207 J.M. Cohen, C. Cane, A. Iordanidou, S. Shibuya, A.-K. Reuschl, I.T. Herczeg, A.C. Argento,  
208 R.G. Wunderink, S.B. Smith, T.A. Poor, C.A. Gao, J.E. Dematte, G.R.S. Budinger, H.K.  
209 Donnelly, N.S. Markov, Z. Lu, G. Reynolds, M. Haniffa, G.S. Bowyer, M. Coates, M.R.  
210 Clatworthy, F.J. Calero-Nieto, B. Göttgens, C. O’Callaghan, N.J. Sebire, C. Jolly, P. De  
211 Coppi, C.M. Smith, A.V. Misharin, S.M. Janes, S.A. Teichmann, M.Z. Nikolić, and K.B.  
212 Meyer, Local and systemic responses to SARS-CoV-2 infection in children and adults. *Nature*  
213 602 (2021) 321-327.
- 214 [13] K. Sacco, R. Castagnoli, S. Vakkilainen, C. Liu, O.M. Delmonte, C. Oguz, I.M. Kaplan, S.  
215 Alehashemi, P.D. Burbelo, F. Bhuyan, A.A. de Jesus, K. Dobbs, L.B. Rosen, A. Cheng, E.  
216 Shaw, M.S. Vakkilainen, F. Pala, J. Lack, Y. Zhang, D.L. Fink, V. Oikonomou, A.L. Snow,  
217 C.L. Dalgard, J. Chen, B.A. Sellers, G.A. Montealegre Sanchez, K. Barron, E. Rey-Jurado, C.

218 Vial, M.C. Poli, A. Licari, D. Montagna, G.L. Marseglia, F. Licciardi, U. Ramenghi, V.  
 219 Discepolo, A. Lo Vecchio, A. Guarino, E.M. Eisenstein, L. Imberti, A. Sottini, A. Biondi, S.  
 220 Mató, D. Gerstbacher, M. Truong, M.A. Stack, M. Magliocco, M. Bosticardo, T. Kawai, J.J.  
 221 Danielson, T. Hulett, M. Askenazi, S. Hu, J. Barnett, X. Cheng, K. Kaladi, V. Kuram, J.  
 222 Mackey, N.M. Bansal, A.J. Martins, B. Palterer, H. Matthews, U. Mudunuri, M. Nambiar,  
 223 A.J. Oler, A. Rastegar, S. Samuel, C. Shyu, V. Waingankar, S. Weber, S. Xirasagar, Y.  
 224 Espinosa, C. Astudillo, C. Piñera, R. González, M. De Filippo, M. Votto, L. Montagna, J.I.  
 225 Cohen, H.C. Su, D.B. Kuhns, M.S. Lionakis, T.M. Snyder, S.M. Holland, R. Goldbach-  
 226 Mansky, J.S. Tsang, and L.D. Notarangelo, Immunopathological signatures in multisystem  
 227 inflammatory syndrome in children and pediatric COVID-19. *Nature Medicine* 28 (2022)  
 228 1050-1062.

229 [14] A. Pierangeli, M. Gentile, G. Oliveto, F. Frasca, L. Sorrentino, L. Matera, R. Nenna, A. Viscido,  
 230 M. Fracella, L. Petrarca, G. D’Ettore, G. Ceccarelli, F. Midulla, G. Antonelli, and C.  
 231 Scagnolari, Comparison by Age of the Local Interferon Response to SARS-CoV-2 Suggests a  
 232 Role for IFN- $\epsilon$  and - $\omega$ . *Frontiers in Immunology* 13 (2022).

233 [15] H. Streeck, B. Schulte, B. Kuehmerer, E. Richter, T. Hoeller, C. Fuhrmann, E. Bartok, R.  
 234 Dolscheid, M. Berger, L. Wessendorf, M. Eschbach-Bludau, A. Kellings, A. Schwaiger, M.  
 235 Coenen, P. Hoffmann, M. Noethen, A.-M. Eis-Huebinger, M. Exner, R. Schmithausen, M.  
 236 Schmid, and G. Hartmann, Infection fatality rate of SARS-CoV-2 infection in a German  
 237 community with a super-spreading event. *Nat Commun* 11 (2020) 5829.

238 [16] C.S. von Bartheld, and L. Wang, Prevalence of Olfactory Dysfunction with the Omicron Variant  
 239 of SARS-CoV-2: A Systematic Review and Meta-Analysis. *Cells* 12 (2023).

240 [17] Q. Yan, D. Qiu, X. Liu, X. Guo, and Y. Hu, Prevalence of Smell or Taste Dysfunction Among  
 241 Children With COVID-19 Infection: A Systematic Review and Meta-Analysis. *Frontiers in*  
 242 *Pediatrics* 9 (2021).

243

## 244 Tables

245 Table 1 Characteristics of the study population

subgroup number	all respondents 101	alpha 12	delta 44	omicron 45
<b>age (years)</b>				
0-6	27 (26.7%)	3 (25%)	14 (31.8%)	10 (22.2%)
7-12	61 (60.4%)	6 (50%)	26 (59.1%)	29 (64.4%)
13-18	13 (12.9%)	3 (25%)	4 (9.1%)	6 (13.3%)
<b>gender</b>				
female	54 (53.5%)	4 (33.3%)	26 (59.1%)	24 (53.3%)
male	47 (46.5%)	8 (66.6%)	18 (40.9%)	21 (46.7%)
<b>smoking</b>				
active	0 (0%)	0 (0%)	0 (0%)	0 (0%)
passive	6 (5.9%)	1 (8.3%)	2 (4.5%)	3 (6.7%)



<b>hayfever<sup>1</sup></b>	4 (3.9%)	0 (0%)	1 (2.3%)	3 (6.7%)
<b>severity</b>				
asymptomatic	6 (5.9%)	1 (8.3%)	5 (11.4%)	0 (0%)
mild <sup>2</sup>	34 (33.7%)	3 (25%)	19 (43.2%)	12 (26.7%)
moderately ill <sup>3</sup>	51 (50.5%)	7 (58.3%)	19 (43.2%)	25 (55.6%)
very ill <sup>4</sup>	10 (9.9%)	1 (8.3%)	1 (2.3%)	8 (17.8%)
hospitalization	0 (0%)	0 (0%)	0 (0%)	0 (0%)
intensive care treatment	0 (0%)	0 (0%)	0 (0%)	0 (0%)

246 <sup>1</sup> hayfever relevant at the time of infection  
 247 <sup>2</sup> e.g. “I did not feel ill but had a runny nose”  
 248 <sup>3</sup> e.g. “I felt ill and lay on the sofa”  
 249 <sup>4</sup> e.g. “I felt very ill and had to stay in bed”

250

## 251 **Figure Legends**

252 **Figure 1 Heatmap of symptoms of SARS-CoV-2-infected children and adolescents.** (A)  
 253 Symptoms of SARS-CoV-2 infected children and adolescents as reported during the alpha (top),  
 254 delta (delta) and omicron dominated phases (bottom) of the SARS-CoV-2 pandemic, responses were  
 255 sorted by variant phase and age of the participant. “feverish/not feverish”: subjective judgement,  
 256 body temperature was not measured. (B) The graph shows the age of the respondents from the alpha,  
 257 delta and omicron variant dominated phases of the SARS-CoV-2 pandemic. Each dot indicates an  
 258 individual, n.s. = not significant ( $P > 0.05$ , One Way ANOVA).

259 **Figure 2 Frequency of symptoms stratified by SARS-CoV-2 variant.** Barplots indicate the  
 260 frequency of the indicated symptoms reported by all respondents (A) or by the respondents infected  
 261 during the alpha, delta or omicron dominated phases (B). \* indicates statistically significant  
 262 differences compared to the frequency during the alpha variant dominated phase, # indicates  
 263 statistically significant differences compared to the frequency during the delta variant dominated  
 264 phase ( $P < 0.05$ , Fisher’s exact test).

265 **Figure 3 Comparison of symptom frequencies reported by adults and children.** The frequencies  
 266 of symptoms reported by adults have been reported before in a previous publication [8] and are  
 267 shown by grey bars. The frequencies of children are shown as purple bars. Significant differences  
 268 between frequencies reported by adults and children are indicated by \* ( $P < 0.05$ , Fisher’s exact test).  
 269 n.a. = not available: data were not acquired in the previous study.

270

## 271 **Conflict of Interest**

272 *The authors declare that the research was conducted in the absence of any commercial or financial*  
 273 *relationships that could be construed as a potential conflict of interest.*

## 274 **Ethics Statement**

275 The studies involving human participants were reviewed and approved by Ethik-Kommission der  
276 Medizinischen Fakultät der Universität Duisburg-Essen Robert-Koch-Str. 9-11 45147 Essen  
277 Germany. The patients/participants provided their informed consent to participate in this study.

### 278 **Author Contributions**

279 HS recruited participants and contributed to writing the manuscript. WB conceived of the study,  
280 created the online survey, analyzed data and wrote the manuscript. All authors contributed to the  
281 article and approved the submitted version.

282


### 283 **Acknowledgments**

284 We would like to thank all participants for taking part in our survey.


285


### 286 **Data Availability Statement**

287 The raw data supporting the conclusions of this article will be made available by the authors, without  
288 undue reservation.




**B**







## alpha in adults vs. children



## delta in adults vs. children



## omicron in adults vs. children



frequency [%]


 adults children